Prices of CD4 assays and viral load tests must be reduced for developing countries

EDITOR—Wise has reported that GlaxoSmithKline is to cut the price of some drugs in developing countries.1 For over a decade antiretroviral treatment has been available to patients in the United States and Europe. Because of the extent of HIV infection in the developing world, however, the cost of these drugs was way beyond the reach of the government treasuries in the world's poorest countries. As a result there was the …